- Home
- CHNR vs INDP Comparison
CHNR vs INDP Comparison
Compare CHNR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | INDP |
|---|---|---|
| Founded | N/A | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.5M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHNR | INDP |
|---|---|---|
| Price | $4.10 | $1.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 768.7K | 17.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.27 |
| 52 Week High | $57.47 | $13.24 |
Technical Indicators
Market Signals| Indicator | CHNR | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 37.58 |
| Support Level | $3.31 | $0.27 |
| Resistance Level | $4.25 | $1.99 |
| Average True Range (ATR) | 0.55 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 32.82 | 7.14 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.